title: In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent.
abstract: This study evaluated the anti-angiogenic activities of erianin in vivo and in vitro. Erianin, a natural product from Dendrobium chrysotoxum, caused moderate growth delay in xenografted human hepatoma Bel7402 and melanoma A375 and induced significant vascular shutdown within 4 h of administering 100 mg/kg of the drug. Erianin also displayed potent anti-angiogenic activities in vitro: it abrogated spontaneous or basic fibroblast growth factor-induced neovascularisation in chick embryo; it inhibited proliferation of human umbilical vein endothelial cells (EC(50) 34.1+/-12.7 nM), disrupted endothelial tube formation, and abolished migration across collagen and adhesion to fibronectin. Erianin also exerted selective inhibition toward endothelial cells, and quiescent endothelium showed more resistance than in proliferative and tumour conditions. In a cytoskeletal study, erianin depolymerised both F-actin and beta-tubulin, more significantly in proliferating endothelial cells than in confluent cells. In conclusion, erianin caused extensive tumour necrosis, growth delay and rapid vascular shutdown in hepatoma and melanoma models; it inhibited angiogenesis in vivo and in vitro and induced endothelial cytoskeletal disorganisation. These findings suggest that erianin has the therapeutic potential to inhibit angiogenesis in vivo and in vitro.
authors.affiliation: Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Zhangjiang Hi-Tech Park, Shanghai 201203, PR China.
authors.forename: Y-Q
authors.initials: YQ
authors.lastname: Gong
authors.forename: Y
authors.initials: Y
authors.lastname: Fan
authors.forename: D-Z
authors.initials: DZ
authors.lastname: Wu
authors.forename: H
authors.initials: H
authors.lastname: Yang
authors.forename: Z-B
authors.initials: ZB
authors.lastname: Hu
authors.forename: Z-T
authors.initials: ZT
authors.lastname: Wang
mesh_terms: D016475:3T3 Cells; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001632:Bibenzyls / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000098:blood supply* / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D005260:Female; D008113:Liver Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D008545:Melanoma / Q000098:blood supply* / Q000188:drug therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D019800:Phenol; D012878:Skin Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D014407:Tumor Cells, Cultured
chemical_list: D020533:Angiogenesis Inhibitors; D001632:Bibenzyls; C477638:Erianin; D019800:Phenol